GSK and iTeos drop anti-TIGIT drug following trial failure
GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a…
Latest News
-
-
GLP-1RAs show anti-cancer benefits beyond weight loss
A study has found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer anti-cancer benefits that extend beyond their role in promoting…
-
Novo Nordisk’s Sogroya matches Norditropin in children’s growth disorders
Novo Nordisk’s once-weekly Sogroya (somapacitan) has proved to be non-inferior to the once-daily growth hormone Norditropin (somatropin) in children’s growth…
-
Sanofi exec tells biotechs not to scrimp on clinical trial design
At a time when the biotech sector has been struggling with a lack of investment, some companies have had to…
-
European biotechs must understand US culture while seeking funding
At a time when the US is becoming more self-focused, European biotechs must understand and appreciate US culture when seeking…
-
Swiss biotech sector’s R&D investment grew in 2024 despite global trends
Research and development (R&D) investment in the Swiss biotech sector grew in 2024, despite ongoing global funding struggles. While many…
-
Eli Lilly’s shares up as oral GLP-1RA scores in first Phase III trial
Eli Lilly’s Phase III trial with its oral weight loss pill, orforglipron, has met its primary endpoint, reducing A1C levels…
-
BMS’ Camzyos flops in Phase III non-obstructive hypertrophic cardiomyopathy trial
Bristol Myers Squibb’s (BMS) Phase III trial investigating Camzyos (mavacamten) in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) has failed to…
-
Pfizer drops obesity pill development after liver injury report
Pfizer has terminated the development of its oral obesity candidate danuglipron after a patient on a clinical trial with the…
-
UK Government to invest $764m into new health data service
The UK Government has announced a £600m ($764m) funding pot to create a new Health Data Research Service, reducing red…
